

WELCOME 2018 Hypertension Symposium



Jeffrey Brettler MD

KP SCal Regional Hypertension Physician Lead

KAISER PERMANENTE.





WHY KEEP TALKING ABOUT HTN?

- HTN is quantitatively the most important risk factor for premature CVD, being more common than smoking, dyslipidemia and diabetes.
- HTN accounts for an estimated 54% of all strokes and 47% of all ischemic heart disease events globally. (Lancet 2008; 371; 1513 - Global Burden of blood pressure related disease 2001).
- Increases the risk for CKD, HF, afib and PVD.



And Treatment Works!

Large scale RCTs show that antihypertensive treatment results in the following:

- 50% reduction in heart failure
- 30-40% reduction in stroke
- 20-25% reduction in MI

BMJ 2008: BP Trialists' BP lowering collaboration



HTN PREVALENCE – SCAL KP

• As of August 2018: 831,780




Changing Landscape of Hypertension

- How do we define?
- How do we diagnose?
- How do we measure?
- What are our goals?
- Which guideline do we follow: JNC 8, ACP/AAFP, ACC/AHA, KP



AA Disparity Gap



KAISER PERMANENTE®

Hypertension: African Americans Compared to Whites

- Higher prevalence
- Earlier onset
- Greater risk for:
 - Fatal and nonfatal stroke
 - Heart disease
 - End-stage renal disease

Saunders et al. Arch Intern Med. 1990;150:1707



Hypertension-Related Morbidity and Mortality in Black Individuals Compared to Whites

Rates for African Americans vs nonblack rates

Overall mortality

Nonfatal stroke

Fatal stroke

Heart disease death

End-stage renal disease

JNC V. Arch intern Med 1993;153:154-183 Cook. Am Heart J. 1988;116:288-295 6-13 times greater

1.3 times greater


3-6 times greater


1.5 times greater

5 times greater



Controlling BP Performance POINT & CSG 2007-2018






2017 HEDIS National Ranking Controlling BP - Commercial Population


Rank	Health Plan Name	ProductLine	ReportingProduct	MeasureName	Rate
1	Kaiser-Mid-Atlantic	Commercial	НМО	Controlling High Blood Pressure	91.82
2	Dean Health Plan, Inc.	Commercial	HMO/EPO Combined	Controlling High Blood Pressure	86.22
3	Kaiser Permanente Colorado	Commercial	НМО	Controlling High Blood Pressure	86.13
4	Kaiser Georgia	Commercial	НМО	Controlling High Blood Pressure	85.99
5	Kaiser - CA (Northern CA)	Commercial	НМО	Controlling High Blood Pressure	83.57
6	Kaiser - HI	Commercial	НМО	Controlling High Blood Pressure	82.8
7	Medical Associates	Commercial	HMO/POS Combined	Controlling High Blood Pressure	82.48
8	Kaiser - CA (Southern CA)	Commercial	НМО	Controlling High Blood Pressure	82.24
9	GHC-SCW	Commercial	НМО	Controlling High Blood Pressure	81.27
10	AultCare	Commercial	НМО	Controlling High Blood Pressure	80.41

HEDIS 2018 Medicare Population




KAISER PERMANENTE.

HEDIS 2018 Controlling BP Results All – Administrative Data




KAISER PERMANENTE.


HEDIS 2018 Controlling BP Results Commercial- Administrative Data



HEDIS 2018 Controlling BP Results Medicare - Administrative Data



Black/African American HTN Control



	2018 Hypertension Symposium				
Hilton Long Beach					
Friday, September 14, 2018					
TIME 7:00 am – 8:00 am	TOPIC Registration/Continental Breakfast				
8:00 am – 9:00 am	New Guidelines Joel Handler, MD & Jeffrey Brettler, MD What are the results of the new landmark studies regarding Hypertension and what are the new treatment quidelines?				
9:00 am – 9:20 am	Q & A for Guidelines				
9:20 am – 10:20 am	Out of Office Blood Pressure Daichi Shimbo, MD What are different BP methodologies, what is the most accurate, how do I use them to identify cardiovascular risk and improved monitoring of treatment?				
10:20 am – 10:40 am	Q & A for Out of Office BP				
10:40 am – 11:00 am	Break & Transition Time				
11:00 am – 12:00 pm	BREAKOUT SESSIONS A				
Session A1	African American Hypertension Care Anna Khachikyan, MD, Ray Nanda, MD, Madalynne Wilkes, MD What tools and techniques can I use to improve communication with my African American hypertensive patients to improve their control rates?				
Session A2	Challenging Cases Maricel Pilapil-Pureza, MD, Mark Rutkowski, MD What are causes of resistant hypertension and how can I use the necessary treatments to improve the outcomes of my patients?				
Session A3	ABPM/AOBP/Telemonitoring Jeffrey Brettler, MD, Que Nguyen, MD How can I use and order the different BP monitoring methodologies?				
12:00 pm – 1:00 pm	LUNCH				
1:00 pm – 2:00 pm	BREAKOUT SESSIONS B				
Session B1	African American Hypertension Care Anna Khachikyan, MD, Ray Nanda, MD, Madalynne Wilkes, MD What tools and techniques can I use to improve communication with my African American hypertensive patients to improve their control rates?				
Session B2	Challenging Cases Maricel Pilapil-Pureza, MD, Mark Rutkowski, MD What are causes of resistant hypertension and how can I use the necessary treatments to improve the outcomes of my patients?				
Session B3	ABPM/AOBP/Telemonitoring Jeffrey Brettler, MD, Que Nguyen, MD How can I use and order the different BP monitoring methodologies?				
2:00 pm – 2:15 pm	Break & Transition Time				
2:15 pm – 3:00 pm	Lifestyle Interventions Sean Hashmi, MD What lifestyle interventions can help improve Blood Pressure and how can I motivate my patients to make lifestyle changes?				
3:00 pm – 3:15 pm	Q & A for Lifestyle				
3:15 pm – 3:45 pm	Reflection: Key Take-Aways from the Day, and Interactive Session Panel What are the Key Points or "Pearls" that I have I have learned?				
3:45 pm – 4:00 pm	Closing Remarks Jeffrey Brettler, MD				



Total CME = 6.5